A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00370552
First received: August 30, 2006
Last updated: April 15, 2013
Last verified: April 2013
  Purpose

The purpose of this clinical research study is to learn if ixabepilone plus bevacizumab is effective in shrinking or stopping the growth of cancer when given as first-line chemotherapy in participants with metastatic breast cancer. The study will also assess the safety of this combination treatment.


Condition Intervention Phase
Metastatic Breast Cancer
Drug: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
Drug: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg
Drug: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Open Label, Randomized, 3 Arm Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab as First Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study [ Time Frame: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression ] [ Designated as safety issue: No ]
    CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions.

  • Number of Participants With Best Response As Assessed With Response Evaluation Criteria in Solid Tumors (RECIST) [ Time Frame: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression ] [ Designated as safety issue: No ]
    Best tumor response was assessed with RECIST. Complete response (CR)=Disappearance of all evidence of target lesions; Partial response (PR)=At least 30% reduction from baseline in the sum of the longest diameter (LD) of all target lesions; Progressive disease (PD)=At least a 20% increase from baseline in the sum of LD of target lesions or the appearance of 1 or more new lesions; Stable disease (SD)=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. A response was confirmed if noted on 2 examinations at least 4 weeks apart.


Secondary Outcome Measures:
  • Percentage of Participants With Progression-free Survival at Week 24 [ Time Frame: Date of randomization to Week 24 ] [ Designated as safety issue: No ]
    Week 24 Progression-free Survival was defined as the number of participants who neither progressed nor died before Week 24. Computed using Kaplan-Meier estimates, only at the time of Interim Analysis, when all participants had been followed for 6 months.

  • Median Progression-free Survival (PFS) [ Time Frame: Date of randomization to date of progression, death, or last tumor assessment (maximum participant PFS of 29 months) ] [ Designated as safety issue: No ]
    PFS was defined as the time from randomization to progression or to death from any cause without prior documentation of progression. Participants who did not progress or die were to be censored on the date of their last tumor assessment.

  • Median Time to Response [ Time Frame: Date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant time to response of 67 weeks) ] [ Designated as safety issue: No ]
    Time to response was defined as the time from the first dose of study therapy until measurement criteria were first met for a PR or CR, whichever was recorded first. Time to response was computed only for participants whose best response was PR or CR.

  • Median Duration of Response [ Time Frame: Date of first PR or CR assessment to date of progression, death, or last tumor assessment (maximum participant duration of response of 25 weeks) ] [ Designated as safety issue: No ]
    Duration of response was computed for participants whose best response was either PR or CR. Duration of overall response was defined as the period from the time that measurement criteria were first met for PR or CR, whichever was recorded first, until the first date of documented PD or death. Participants who neither relapsed nor died were to be censored on the date of their last tumor assessment.

  • Percentage of Participants Surviving at 1 Year [ Time Frame: Date first participant enrolled to 1 year ] [ Designated as safety issue: No ]
    One year survival rates were computed using Kaplan-Meier estimates.

  • Number of Participants With Death as Outcome, Serious Adverse Events (SAEs) Treatment-related SAEs, Treatment-related Adverse Events (AEs) Leading to Discontinuation, AEs Leading to Discontinuation, Treatment-related AEs [ Time Frame: At initiation of treatment throughout study, to a minimum of 30 days after last dose of study drug ] [ Designated as safety issue: Yes ]
    An AE is any new untoward medical occurrence or worsening of a preexisting medical condition that does not necessarily have a causal relationship with this treatment. An SAE is any untoward medical event that at any dose: results in death, persistent or significant disability/incapacity, drug dependency or abuse; is life-threatening, an important medical event, a congenital anomaly/birth defect; requires inpatient hospitalization; or prolongs existing hospitalization. Treatment related=possibly, probably, or certainly related to and of unknown relationship to study treatment.

  • Number of Participants With Abnormalities in Hematology Laboratory Results by Worst Common Terminology Criteria (CTC) Grade [ Time Frame: At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle ] [ Designated as safety issue: Yes ]
    CTC, Version 3 used to assess parameters. CTC Gr=Grade; WBC=white blood cells; ANC=absolute neutrophil count. LLN=lower level of normal. WBC Gr 1:<LLN to 3.0*10^9/L, Gr 2:<3.0 to 2.0*10^9/L, Gr 3:<2.0 to 1.0*10^9/L, Gr 4:<1.0*10^9/L; ANC Gr 1:<LLN to 1.5*10^9/L, Gr 2:<1.5 to 1.0*10^9/L, Gr 3:<1.0 to 0.5*10^9/L, Gr 4:<0.5*10^9/L; Platelet count Gr 1:LLN to 75.0*10^9/L, Gr 2:<75.0 to 50.0*10^9/L, Gr 3:<50.0 to 25.0*10^9/L, Gr 4:<25.0 to 10^9/L; Hemoglobin Gr 1:<LLN to 10.0 g/dL, Gr 2:<10.0 to 8.0 g/dL, Gr 3:<8.0 to 6.5 g/dL, Gr 4:<6.5 g/dL.

  • Number of Participants With Abnormalities in Liver Function by Worst CTC Grade [ Time Frame: At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle ] [ Designated as safety issue: Yes ]
    ULN=Upper limit of normal.ALT Gr 1:>ULN to 2.5*ULN, Gr 2: >2.5 to 5.0*ULN, Gr 3: >5.0 to 20.0*ULN, Gr 4: >20.0*ULN; AST Gr 1: >ULN to 2.5*ULN, Gr 2: >2.5 to 5.0*ULN, Gr 3: >5.0 to 20.0*ULN, Gr 4: >20.0*ULN; ALP Gr 1:>ULN to 2.5*ULN, Gr 2: >2.5 to 5.0*ULN, Gr 3: >5.0 to 20.0*ULN, Gr 4: >20.0*ULN; Total bilirubin Gr 1: >ULN to 1.5*ULN, Gr 2: >1.5 to 3.0*ULN, Gr 3: >3.0 to 10.0*ULN, Gr 4: >10.0*ULN.

  • Number of Participants With Abnormalities in Renal Function by Worst CTC Grade [ Time Frame: At initiation of treatment and throughout study, to a minimum of 30 days after last dose of study drug. Laboratory tests performed within 72 hours before start of each cycle ] [ Designated as safety issue: Yes ]
    Creatine Gr 1: >ULN to 1.5*ULN, Gr 2: 1.5 to 3.0*ULN, Gr 3: >3.0 to 6.0*ULN, Gr 4: >6.0*ULN.


Enrollment: 136
Study Start Date: March 2007
Study Completion Date: November 2009
Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg Drug: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg
Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Other Names:
  • IXEMPRA
  • BMS-247550
Experimental: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg Drug: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg
Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Other Names:
  • IXEMPRA
  • BMS-247550
Active Comparator: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg Drug: Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
Other Names:
  • TAXOL
  • BMS-181339

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Locally recurrent or metastatic breast cancer, previously untreated with chemotherapy for advanced disease.
  • At least 1 target lesion per RECIST criteria. Locally recurrent disease must not be amenable to resection with curative intent.
  • No previous cytotoxic chemotherapy for locally recurrent/metastatic disease.
  • Relapse 12 months or more after completing prior adjuvant or neoadjuvant taxane therapy.
  • No previous breast cancer known to overexpress or amplify the human epidermal growth factor receptor 2 gene.
  • Prior hormonal therapy in adjuvant, recurrent, or metastatic setting allowed but must have been discontinued at least 2 weeks before randomization.
  • Karnofsky performance status of 80 to 100 or Eastern Cooperative Oncology Group performance status of 0 to 1.
  • Estimated life expectancy of at least 12 weeks.
  • Recovery from recent therapy (except for alopecia), including chemotherapy, immunotherapy, biologic therapy, or investigational product. Any such therapy must have been completed at least 3 weeks before randomization and at least 6 weeks from use of nitrosourea, or mitomycin.
  • Recovery from recent surgery and radiation therapy. At least 1 week since minor surgery and/or focal/palliative radiation therapy; at least 3 weeks from radiation; at least 4 weeks from major surgery; and at least 8 weeks from liver resection, thoracotomy, or neurosurgery.
  • Absolute neutrophil count ≥1500/mm^3.
  • Hemoglobin ≥9 g/dL.
  • Platelets ≥100,000/mm^3.
  • Total bilirubin ≤1.5 times the upper limit of normal (ULN).
  • Aspartate aminotransferase or alanine aminotransferase ≤2.5*ULN.
  • Normal partial thromboplastin time and either international normalized ratio or prothrombin time <1.5*ULN.
  • Serum creatinine ≤1.5*ULN or 24-hour creatinine clearance >60 mL/min.
  • Urine dipstick for proteinuria <2+ (negative, trace, or +1). Participants with ≥2+ proteinuria at baseline were to undergo 24-hour urine collection and demonstrate ≤1g of protein in 24 hours to be eligible.

Exclusion criteria:

  • Women of child-bearing potential (WOCBP) unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 6 months after treatment with bevacizumab.
  • Women who were pregnant or breastfeeding.
  • Women with a positive pregnancy test on enrollment or prior to study drug administration.
  • Sexually active fertile men, whose partners were WOCBP, not using an adequate method of birth control.
  • Evidence of baseline sensory or motor neuropathy.
  • Serious infection or nonmalignant medical illnesses uncontrolled or the control of which could be jeopardized by this therapy.
  • History of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, serious gastric ulcer, or bone fracture within 6 months of study entry.
  • History of hypertensive crisis or hypertensive encephalopathy.
  • Significant vascular disease.
  • Clinically significant cardiovascular disease.
  • Baseline left ventricular ejection fraction by multiple-gated acquisition scan or echocardiogram for subjects with prior exposure to anthracyclines not within institutional normal limits.
  • Symptomatic peripheral vascular disease.
  • History of high dose chemotherapy with bone marrow transplant or peripheral blood stem cell transplant within the previous 2 years.
  • Evidence of bleeding diathesis or coagulopathy.
  • Prior treatment with an epothilone or any antiangiogenic agent.
  • Concurrent nonhealing wound, ulcer, or fracture.
  • Any current or history of brain and/or leptomeningeal metastases. Psychiatric disorders or other conditions rendering the participant incapable of complying with the requirements of the protocol.
  • Any concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix.
  • Known allergy to any of the study drugs or their excipients.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00370552

Locations
United States, California
East Valley Hematology And Oncology Medical Group
Burbank, California, United States, 91505
Wilshire Oncology Medical Group, Inc.
La Verne, California, United States, 91750
Ucsf-Comprehensive Cancer Center
San Francisco, California, United States, 94115
United States, Iowa
University Of Iowa Hospitals And Clinics
Iowa City, Iowa, United States, 52242
United States, Missouri
Ellis Fischel Cancer Center
Columbia, Missouri, United States, 65203
United States, New York
Weill Medical College Of Cornell University
New York, New York, United States, 10021
France
Local Institution
Besancon Cedex, France, 25030
Local Institution
Clermont-Ferrand, France, 63000
Local Institution
Marseille Cedex 9, France, 13273
Local Institution
Paris Cedex 10, France, 75475
Local Institution
Saint Herblain, France, 44805
Local Institution
Strasbourg Cedex, France, 67085
Local Institution
Tours Cedex, France, 37044
Italy
Local Institution
Cuneo, Italy, 12100
Local Institution
Meldola Fc, Italy, 47014
Local Institution
Milano, Italy, 20132
Local Institution
Modena, Italy, 41100
Local Institution
Napoli, Italy, 80131
Local Institution
Roma, Italy, 00161
Spain
Local Institution
Hospitalet De Llobregat, Spain, 08907
Local Institution
Jaen, Spain, 23007
United Kingdom
Local Institution
Chelmsford, Essex, United Kingdom, CM1 7ET
Local Institution
Manchester, Greater Manchester, United Kingdom, M20 4BX
Local Institution
Nottingham, Nottinghamshire, United Kingdom, NG5 1PB
Local Institution
Merseyside, United Kingdom, CH63 4JY
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided

Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00370552     History of Changes
Other Study ID Numbers: CA163-115
Study First Received: August 30, 2006
Results First Received: March 24, 2011
Last Updated: April 15, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Bevacizumab
Paclitaxel
Epothilones
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Growth Inhibitors
Antineoplastic Agents
Therapeutic Uses
Antineoplastic Agents, Phytogenic
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014